Dr. Kouros Motamed is an experienced cancer biologist with proven record of success in directing scientific productivity of multi-disciplinary research teams in academic and industry settings. Dr. Motamed was the Assistant Professor in the Vascular Biology Center & Dept. of Pathology of Georgia Health Sciences University from 2002 to 2007, where he established novel in vitro co-culture systems of ovarian cancer cells, primary mesothelial cells and macrophages to test the inhibitory function of novel proteins and small molecules. He also initiated and managed multi-disciplinary in-house and outside collaborations to evaluate the role of extracellular matrix proteins in mouse models of Hypertension (DOCA salt and Angiotensin II), Diabetes (STZ, ob/ob), Flow-induced Vascular Remodeling, and Stroke (transient middle cerebral arter occlusion, MCAO). He established mouse models of early and late stage ovarian and prostate cancer to study the molecular signaling of tumor growth and metastasis. After his term in Georgia Health Sciences University, Dr. Motamed has been appointed as a Principal Scientist in Abraxis BioScience, where he headed the Molecular Biology Group researching in Generation and evaluation of novel in-house and licensed drug delivery systems with extensive experience in design and execution of MOA studies for FDA filings along with establishment and validation of IHC biomarkers in support of FDA filings. In 2012, he joined in Biomiga Diagnostics (A Start-Up Personalized Medicine Diagnostics Company) as the Chief Technical Officer where he directed assay design, sales and marketing of Point-of-Care, Therapeutic Drug Monitoring (TDM) medical tests; and formulated long-term visions and strategies for personalized medicine product lines. Then he joined IGDRASOL, Inc. (A Start-Up Personalized Nanomedicine Therapeutic Company), as Chief Scientific Officer where he licensed two Phase 3-ready nanoparticle paclitaxel formulations for US FDA approval and directed the design & formulation of mAb-targeted paclitaxel nanoparticles. At present, after official merging IGDRASOL, Inc. with Sorrento Therapeutics, Inc.; Dr. Motamed has been appointed as VP of Clinical Development & Nanomedicine. Dr. Kouros Motamed has edited over 30 peer-reviewed publications in high impact journals, has over 40 published abstracts and 5 patents/patent applications.

The research interests of Dr. Kouros Motamed include:

• Drug Discovery/Development
• Biomarker Development
• Point-of-Care Diagnostics
• Personalized Nanomedicine